Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.62 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30694681 | 1.00 | SLC7A5 (0.62) | SLC7A5LOXL2CYP4F2CYP4A11MRGPRX4 | |
| SCHEMBL12301533 | 0.87 | SLC7A5 (0.65) | SLC7A5LOXL2CYP4F2CYP4A11MRGPRX4 | |
| SCHEMBL7384982 | 0.85 | SLC7A5 (0.63) | SLC7A5LOXL2CYP4F2CYP4A11MRGPRX4 | |
| SCHEMBL3499880 | 0.85 | SLC7A5 (0.63) | SLC7A5LOXL2CYP4F2CYP4A11MRGPRX4 | |
| SCHEMBL27775507 | 0.84 | ALDH1A1 (0.58) | SLC7A5LOXL2CYP4F2CYP4A11MRGPRX4 | |
| SCHEMBL4928282 | 0.84 | LOXL2 (0.69) | SLC7A5LOXL2CYP4F2CYP4A11MRGPRX4 | |
| SCHEMBL29471996 | 0.84 | SLC7A5 (0.62) | SLC7A5LOXL2CYP4F2CYP4A11MRGPRX4 | |
| SCHEMBL22019046 | 0.84 | SLC7A5 (0.62) | SLC7A5LOXL2CYP4F2CYP4A11MRGPRX4 | |
| SCHEMBL10431445 | 0.84 | SLC7A5 (0.62) | SLC7A5LOXL2CYP4F2CYP4A11MRGPRX4 | |
| SCHEMBL127411 | 0.84 | SLC7A5 (0.62) | SLC7A5LOXL2CYP4F2CYP4A11MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313532-A1 | ALDH2 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-10-09 | — | — | US | disclosed |
| US-12378186-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-05 | — | — | US | disclosed |
| WO-2025106949-A1 | WRN INHIBITORS | RADD PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-3967679-B1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | VIVORYON THERAPEUTICS AG (DE) | 2025-02-19 | — | — | EP | disclosed |
| CN-114605404-B | Novel thiazole-containing compound, intermediate and application thereof | 合肥美诺医药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023235753-A2 | ALDH2 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-12-07 | — | — | WO | disclosed |
| CN-115784993-A | Preparation of 3-aminoindazole compound and application thereof in treating Parkinson's disease | 四川大学华西医院 | 2023-03-14 | — | — | CN | disclosed |
| US-11465965-B2 | Double-headed protease inhibitor | UBE INDUSTRIES, LTD. (JP) | 2022-10-11 | — | — | US | disclosed |
| CN-114605404-A | Novel thiazole-containing compound, intermediate and application thereof | 苏州美诺医药科技有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-1242081-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2003090691-A2 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1242081-A1 | CASPASES AND APOPTOSIS | SmithKline Beecham Corporation (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121316-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | SLC7A5 3230/4885LOXL2 4057/4885CYP4F2 1126/4885 |
| US-11465965-B2 | Double-headed protease inhibitor | TMPRSS15, SPINT2, PRSS2 | SLC7A5 690/4885LOXL2 2018/4885CYP4F2 3247/4885 |
| US-20250313532-A1 | ALDH2 INHIBITORS AND METHODS OF USE THEREOF | ADH1A, ALDH1A1, ADH1C | SLC7A5 326/4885LOXL2 1894/4885CYP4F2 45/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | SLC7A5 3402/4885LOXL2 3647/4885CYP4F2 1268/4885 |
| US-12378186-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | SLC7A5 3381/4885LOXL2 873/4885CYP4F2 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.